If you liked this article you might like

Biotech Premarket Movers: Cempra, Tesaro, Editas
Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer
AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results
Incyte Pops on Continued Gilead Takeout Speculation